💊AI-Discovered Drug Rentosertib Shows Positive Phase IIa Results For Pulmonary Fibrosis
AI-Discovered Drug Rentosertib Shows Positive Phase IIa Res…
TL;DR
Nature Medicine published the first-ever Phase IIa results for a fully AI-discovered drug, rentosertib (ISM001-055), for idiopathic pulmonary fibrosis.
Nature Medicine published the first-ever Phase IIa results for a fully AI-discovered drug, rentosertib (ISM001-055), for idiopathic pulmonary fibrosis. Results show a 98.4 mL FVC improvement at the 60mg dose versus a 62.3 mL decline for placebo over 12 weeks.
Key Points
First Phase IIa readout for a fully AI-discovered drug
+98.4 mL FVC at 60mg vs -62.3 mL placebo over 12 weeks
Published in Nature Medicine
Why It Matters
A positive Phase IIa readout from an AI-discovered compound validates the computational drug design thesis and is likely to reallocate billions in pharma R&D toward AI-first programs.
Frequently Asked Questions
Why does this matter?
A positive Phase IIa readout from an AI-discovered compound validates the computational drug design thesis and is likely to reallocate billions in pharma R&D toward AI-first programs.
What happened?
Nature Medicine published the first-ever Phase IIa results for a fully AI-discovered drug, rentosertib (ISM001-055), for idiopathic pulmonary fibrosis.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.
Join 3,041 builders reading daily.